Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03236545 · ClinicalTrials.gov registry record · NA
Menopause Effects on Vascular Function
A NA study of Cardiovascular Risk Factor, sponsored by University of Delaware.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT03236545: Completed NA study of Cardiovascular Risk Factor, sponsored by University of Delaware.
NCT03236545 is a NA study of Cardiovascular Risk Factor that has completed, run by University of Delaware. The registered enrollment target is 48 participants, below the 3,067-participant average among 31 other Cardiovascular Risk Factor trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03236545, a NA study of Cardiovascular Risk Factor, has completed, sponsored by University of Delaware.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to identify the independent effect of estradiol (E2) on endothelin-1 (ET-1) mediated vasomotor function in women. The study is the first step in recognizing the impact of ovarian hormones on the mechanisms that regulate vascular function in women to provide a better understanding of the cardiovascular efficacy of hormone therapy.
Primary Outcome
The capacity of the small and large blood vessels to dilate.
Conditions Studied
Interventions
- OTHER No to Low Endogenous Estrogen
- OTHER Estradiol
Study Locations (1)
Delaware
- University of Delaware - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2016-07-01 |
| Est. Completion | 2022-11-01 |
| Phase | NA |
What the finished NCT03236545 record still lists
NCT03236545 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 3,067-participant average among 31 other Cardiovascular Risk Factor trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Cardiovascular Risk Factor appearing as the primary indexed condition, and to 2 interventions - of which No to Low Endogenous Estrogen is the first listed.
NCT03236545 reports a single indexed study location in Delaware.
Frequently Asked Questions
What is clinical trial NCT03236545 about?
NCT03236545 is a clinical study titled "Menopause Effects on Vascular Function". The purpose of the study is to identify the independent effect of estradiol (E2) on endothelin-1 (ET-1) mediated vasomotor function in women. The study is the first step in recognizing the impact of ovarian hormones on the mechanisms that regulate vascular function in women to provide a better under...
What is the current status of trial NCT03236545?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2016-07-01. Estimated completion is 2022-11-01.
What conditions does trial NCT03236545 study?
This clinical trial studies the following conditions: Cardiovascular Risk Factor.
What interventions are being tested in trial NCT03236545?
The interventions under investigation include: No to Low Endogenous Estrogen (OTHER), Estradiol (OTHER).
Who is sponsoring clinical trial NCT03236545?
This trial is sponsored by University of Delaware, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03236545 being conducted?
This trial has 1 study location across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Risk Factor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03236545's enrollment target sits among peer trials
48 20th of 31 higher than 12 of 31 other Cardiovascular Risk Factor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Risk Factor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
RECRUITING · NA
-
The Influence of Mitochondrial-Derived Reactive Oxygen Species on Racial Disparities in Neurovascular Function
RECRUITING · NA
-
Sleep Duration and Cardiovascular Health
RECRUITING · NA
-
The Potassium Supplementation Study
RECRUITING · NA
-
Mechanisms Underlying the Protective Vascular Effects of Dietary Potassium in Humans
RECRUITING · NA
-
Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI